Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Unicancer
This publication has 35 references indexed in Scilit:
- The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwideInternational Journal of Cancer, 2024
- Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG studyBreast Cancer Research and Treatment, 2024
- Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3Annals of Oncology, 2024
- Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohortBreast Cancer Research and Treatment, 2024
- Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution studyBreast Cancer Research and Treatment, 2022
- Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast CancerClinical Breast Cancer, 2021
- Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cellsBreast Cancer, 2020
- Decreased ER dependency after acquired resistance to CDK4/6 inhibitorsBreast Cancer, 2020
- Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A reviewInternational Journal of Cancer, 2018
- A principal component method to impute missing values for mixed dataAdvances in Data Analysis and Classification, 2014